Intas Pharmaceuticals Limited — Irbesartan Exporter Profile
Indian Pharmaceutical Exporter · #9 for Irbesartan · $1.8M export value · DGFT Verified
Intas Pharmaceuticals Limited is the #9 Indian exporter of Irbesartan with $1.8M in export value and 156 verified shipments. Intas Pharmaceuticals Limited holds a 1.7% market share in Irbesartan exports across 5 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.
Intas Pharmaceuticals Limited — Irbesartan Export Profile: Buyers & Destinations
Where Does Intas Pharmaceuticals Limited Export Irbesartan?
| Country | Value | Shipments | Share |
|---|---|---|---|
| PHILIPPINES | $1.2M | 38 | 80.6% |
| UNITED KINGDOM | $149.0K | 27 | 10.3% |
| NETHERLANDS | $116.7K | 46 | 8.1% |
| ITALY | $14.4K | 3 | 1.0% |
| MALTA | $457 | 42 | 0.0% |
Intas Pharmaceuticals Limited exports Irbesartan to 5 countries. The largest destination is PHILIPPINES accounting for 80.6% of Intas Pharmaceuticals Limited's Irbesartan shipments, followed by UNITED KINGDOM (10.3%) and NETHERLANDS (8.1%). These destinations reflect Intas Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Irbesartan from Intas Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| ONE DEXCEL PHARMA INC. | PHILIPPINES | $817.1K | 28 |
| TO THE ORDER | PHILIPPINES | $233.0K | 8 |
| ACCORD UK | UNITED KINGDOM | $148.9K | 19 |
| ONE DEXCEL PHARMA INC | PHILIPPINES | $112.3K | 3 |
| BROCACEF NL : HUB | NETHERLANDS | $55.9K | 19 |
| ALLOGA FRANCE | NETHERLANDS | $52.0K | 23 |
| ACCORD HEALTHCARE ITALIA SRL. | ITALY | $9.6K | 1 |
| BROCACEF NL:HUB | NETHERLANDS | $8.8K | 4 |
| ACCORD HEALTHCARE ITALIA SRL | ITALY | $4.8K | 2 |
| PHARMADOX HEALTHCARE LTD | MALTA | $443 | 40 |
Intas Pharmaceuticals Limited supplies Irbesartan to 12 buyers globally. The largest buyer is ONE DEXCEL PHARMA INC. (PHILIPPINES), followed by TO THE ORDER (PHILIPPINES) and ACCORD UK (UNITED KINGDOM). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Irbesartan Export Value and How Much Does Intas Pharmaceuticals Limited Contribute?
India exported $58.2M worth of Irbesartan through 2,669 shipments from 123 suppliers to 68 countries, serving 366 buyers globally. Intas Pharmaceuticals Limited contributes $1.8M to this total, accounting for 1.7% of India's Irbesartan exports. Intas Pharmaceuticals Limited ships Irbesartan to 5 countries through 12 buyers.
What Is the Average Shipment Value for Intas Pharmaceuticals Limited's Irbesartan Exports?
Intas Pharmaceuticals Limited's average Irbesartan shipment value is $11.5K per consignment, based on 156 shipments totaling $1.8M. The largest destination is PHILIPPINES (80.6% of Intas Pharmaceuticals Limited's Irbesartan exports).
How Does Intas Pharmaceuticals Limited Compare to Other Indian Irbesartan Exporters?
Intas Pharmaceuticals Limited ranks #9 among 123 Indian Irbesartan exporters with a 1.7% market share. The top 3 exporters are MYLAN LABORATORIES LIMITED ($10.8M), MACLEODS PHARMACEUTICALS LTD ($8.9M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($8.3M). Intas Pharmaceuticals Limited processed 156 shipments to 5 destination countries.
What Irbesartan Formulations Does Intas Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARMA DRUG&MED:VIRBEZ 300(IRBESARTAN 30 | $183.8K | 6 |
| PHARM DRUG&MED:VIRBEZ 300(IRBESARTAN 300MG TAB EACH FILM COATED TABLET CONT:IRBESARTAN PH.EUR 300MG COL:TITANI(ASPERINV)NOS | $156.6K | 6 |
| PHARM DRUG&MED VIRBEZ 300 (IRBESARTAN 300MG TABLETS EACH FILM COATED TABLET CONT:IRBESARTAN PH.EUR 300MG COLOU(ASPERINV) | $144.6K | 3 |
| PHARMA DRUG&MED:BELIZAR 300 IRBESARTAN2X | $123.6K | 4 |
| PHARM DRUG&MED:VIRBEZ 300 (IRBESARTAN 300MG TABLETS EACH FILM COATED TABLET CONT:IRBESARTAN PH.EUR. 300 MG(ASPERINV) | $100.0K | 2 |
| PHARMA DRUGS & MEDI Irbesartan 150 mg Fi | $73.6K | 3 |
| PHARMA DRUGS & MEDI IRBESARTAN 150 MG FILM-COATED TABLETS AS PER INVOICENOS | $54.6K | 6 |
| PHARM DRUG&MED:VIRBEZ 300(IRBESARTAN 300MG TABLETS EACH FILM COATED TABLET CONT:IRBESARTAN PH.EUR 300MG COLOUR(ASPERINV) | $52.4K | 2 |
| PHARMACEUTICAL DRUGS AND MEDICINE VIRBEZ 300 IRBESARTAN 300MG TABLETS AS PERINVOICE | $50.0K | 1 |
| PHARM DRUG&MED:VIRBEZ 300 IRBESARTAN 300MG TABLETS ECH FLM CTD TAB CONT-IRBESARTAN PH.EUR. 300 MG.. ASPERINV | $50.0K | 1 |
Intas Pharmaceuticals Limited exports 64 distinct Irbesartan formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMA DRUG&MED:VIRBEZ 300(IRBESARTAN 30 with 6 shipments worth $183.8K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Irbesartan to Key Markets
What Intas Pharmaceuticals Limited must comply with to export Irbesartan to its top destination countries
United Kingdom — MHRA
Approval Process
Post-Brexit UK Marketing Authorisation via national procedure. Separate from EU approval since January 2021.
Timeline: 12–15 months
GMP & Export Requirements
UK GMP compliance; MHRA inspection of manufacturing site
Manufacturer Import Authorisation (MIA) held by UK importer; Qualified Person (QP) batch release
Note: Post-Brexit: EU GMP certificates no longer automatically valid in UK. Separate MHRA recognition required.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Intas Pharmaceuticals Limited Compare to Nearest Irbesartan Exporters?
Exporters ranked immediately above and below #9 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 7 | AUROBINDO PHARMA LTD | $2.7M | 251 | 4 | $10.7K |
| 8 | ZYDUS LIFESCIENCES LIMITED | $2.4M | 162 | 6 | $15.1K |
| 9 | INTAS PHARMACEUTICALS LIMITED ★ | $1.8M | 156 | 5 | $11.5K |
| 11 | JUBILANT GENERICS LIMITED | $1.3M | 84 | 7 | $15.1K |
| 12 | MICRO LABS LIMITED | $1.3M | 41 | 6 | $30.8K |
Intas Pharmaceuticals Limited ranks #9 among 123 Indian Irbesartan exporters. Average shipment value of $11.5K compared to the market average of $473.0K. The closest competitors by value are AUROBINDO PHARMA LTD and ZYDUS LIFESCIENCES LIMITED.
Which Indian Ports Ship Irbesartan Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 284 | 10.6% |
| SAHAR AIR | 197 | 7.4% |
| SAHAR AIR CARGO ACC (INBOM4) | 170 | 6.4% |
| JNPT/ NHAVA SHEVA SEA | 147 | 5.5% |
| DELHI AIR | 135 | 5.1% |
| DELHI AIR CARGO ACC (INDEL4) | 133 | 5.0% |
| JNPT | 129 | 4.8% |
| MUNDRA SEA (INMUN1) | 108 | 4.0% |
Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Irbesartan Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)
Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.
Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.
About Intas Pharmaceuticals Limited
Intas Pharmaceuticals Limited exports 75 products worth $372.3M. Beyond Irbesartan, top products include Ras, Mycophenolate, Tacrolimus, Apixaban, Ezetimibe. View the complete Intas Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Irbesartan — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Irbesartan shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Intas Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 156 individual customs records matching Intas Pharmaceuticals Limited exporting Irbesartan, covering 64 formulations to 5 countries via 12 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 68+ countries, 366+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Irbesartan Export Data from Intas Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Limited's Irbesartan exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Intas Pharmaceuticals Limited
Full Company Profile →
75 products · $372.3M total trade · 19 categories
Irbesartan Stats
Company Overview
Top Products by Intas Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Irbesartan. For current shipment-level data, contact TransData Nexus.